Clinical Trial Update: Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

View source ↗

Summary

A clinical trial update reports the risk of Nephrogenic Systemic Fibrosis in patients with moderate renal insufficiency following administration of Magnevist (g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Nephrogenic Systemic Fibrosis

Drugs mentioned

• Magnevist (gadopentetate dimeglumine)

Snippet

Sponsor: Bayer | Conditions: Fibrosis, Kidney Failure | Status: COMPLETED | Results posted: 2014-09-22